Valuation: Eli Lilly and Company

Capitalization 698B 596B 556B 514B 957B 59,847B 1,069B 6,651B 2,531B 27,960B 2,619B 2,564B 102,303B P/E ratio 2025 *
36.6x
P/E ratio 2026 * 27.6x
Enterprise value 723B 618B 575B 532B 991B 61,973B 1,107B 6,888B 2,621B 28,953B 2,712B 2,655B 105,938B EV / Sales 2025 *
12.1x
EV / Sales 2026 * 9.93x
Free-Float
99.81%
Yield 2025 *
0.76%
Yield 2026 * 0.85%
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Eli Lilly and Company

1 day+1.11%
1 week+1.07%
Current month+1.03%
1 month+1.79%
3 months+4.49%
6 months-1.54%
Current year+2.02%
More quotes
1 week 762.03
Extreme 762.03
794
1 month 755.56
Extreme 755.56
825
Current year 677.09
Extreme 677.0912
935.62
1 year 677.09
Extreme 677.0912
972.53
3 years 296.32
Extreme 296.32
972.53
5 years 129.21
Extreme 129.21
972.53
10 years 64.18
Extreme 64.18
972.53
More quotes
Manager TitleAgeSince
Chief Executive Officer 57 2016-12-31
President - -
Director of Finance/CFO 48 2024-09-08
Director TitleAgeSince
Director/Board Member 65 2004-12-31
Director/Board Member 69 2009-03-31
Director/Board Member 53 2011-12-11
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.07%+1.07%-15.54%+137.89% 698B
-0.03%+0.12%+5.91%-12.67% 375B
+0.41%-0.20%+13.28%+24.24% 335B
-1.53%+0.35%-54.14%+9.26% 313B
+0.89%-0.04%+6.30%-20.36% 259B
-0.16%-0.89%+0.47%+17.53% 240B
+0.21%-0.27%-13.25%-7.10% 217B
+3.01%+1.78%-33.47%-11.08% 204B
-0.14%+0.01%-6.03%+19.81% 160B
-0.53%+0.63%-8.08%-51.82% 146B
Average +0.29%+0.74%-10.45%+10.57% 294.8B
Weighted average by Cap. +0.37%+0.50%-10.60%+31.64%
See all sector performances

Financials

2025 *2026 *
Net sales 59.78B 51.07B 47.59B 44.01B 81.92B 5,125B 91.57B 570B 217B 2,394B 224B 220B 8,760B 71.51B 61.09B 56.93B 52.65B 97.99B 6,131B 110B 681B 259B 2,864B 268B 263B 10,480B
Net income 19.22B 16.42B 15.3B 14.15B 26.33B 1,647B 29.44B 183B 69.67B 770B 72.08B 70.59B 2,816B 25.28B 21.59B 20.12B 18.61B 34.64B 2,167B 38.72B 241B 91.65B 1,012B 94.82B 92.86B 3,705B
Net Debt 24.8B 21.19B 19.75B 18.26B 33.99B 2,126B 38B 236B 89.92B 993B 93.04B 91.11B 3,635B 12.25B 10.46B 9.75B 9.02B 16.78B 1,050B 18.76B 117B 44.39B 490B 45.93B 44.98B 1,794B
More financial data * Estimated data
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
Employees
47,000
More about the company
Date Price Change Volume
25-07-09 787.23 $ +1.23% 1,739,927
25-07-08 777.66 $ +0.62% 3,301,776
25-07-07 772.87 $ -1.00% 2,576,881
25-07-03 780.67 $ +0.18% 1,450,772
25-07-02 779.28 $ +0.44% 1,978,285

Delayed Quote Nyse, July 09, 2025 at 03:27 pm EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
777.66USD
Average target price
951.98USD
Spread / Average Target
+22.42%
Consensus

Quarterly revenue - Rate of surprise